Memory improvements and pharmacological treatment: a method to distinguish direct effects on memory from secondary effects due to attention improvement.
Chronic cerebrovascular disturbances of the aged are characterized by a decline of attention. When these patients undergo pharmacological treatment, it is very difficult to distinguish between a direct benefit and/or a secondary effect on memory resulting from attention improvement. In our study we have proposed and evaluated a new method for identifying the different components of therapeutic efficacy on memory and attention in chronic cerebrovascular patients. This method is based on the use of the Randt Memory Test, traditional scores of memory efficiency (Acquisition, Recall, and a combined index), and the RMT three-factor scores derived from a structural model of memory functioning. The three scores have been called Encoding and Organization, Cognitive Efficiency, and Attention Efficiency. Participants were 96 selected chronic cerebrovascular patients treated in a double-blind study for 12 weeks with dihydroergocristine versus placebo. While changes in both acquisition and recall scores were related to the treatment, only changes of the Encoding and Organization factor scores were systematically related to therapy. Changes in Attention Efficiency were positively related to therapy only in proportion to the degree of cerebrovascular impairment.
Fioravanti
M
M
Institute of Psychology, Faculty of Medicine, University of Rome La Sapienza, Italy.
Di Cesare
F
F
D001288:Attention / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D004088:Dihydroergotoxine / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D015987:Effect Modifier, Epidemiologic; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D008959:Models, Neurological; D012680:Sensitivity and Specificity
D004088:Dihydroergotoxine